Issn  2249-7579
e Issn  2249-7579
Publisher JOURNAL OF PHARMACEUTICAL BIOLOGY

A REVIEW OF CHRONIC MYELOID LEUKAEMIA AND ITS PHARMACOTHERAPY

Nabeel Khan
Department of Pharmacy, Health and Well Being, University of Sunderland, England, United Kingdom
Atta Abbas
Department of Pharmacy, Health and Well Being, University of Sunderland, England, United Kingdom

Chronic myeloid leukaemia ,CML ,Pharmacotherapy ,

Chronic myeloid leukaemia CML is a neoplastic disease which fallout from alteration in DNA of a particular bone marrow cell.The phases of the disease include a chronic, accelerated and a blast phase. It is a relatively rare nature of cancer. The disease commonly affects persons between ages of 40 and 60 years.The symptoms of disease are not specified as the chronic phase of CML is almost symptomless and the blast phase show prominent symptoms. A number of haematological and molecular lab finding can augment the diagnosis.Supportive therapy goes parallel in all three phases of CML and that includes transfusion of RBCs and this imparts a symptomatic treatment and may improve quality of life. The main purpose of using drugs is to delay the disease progression. A number of medications are available which form the part of pharmacotherapy of the disease. Research is still investigating the disease and may provide new ways to manage CML more effectively and efficiently.

4 , 2 , 2014

65 - 67